Hopes Rise For Approval Of Melanoma Drug Ipilimumab, With Positive Front-line Results

As Bristol-Myers' ipilimumab nears its March 26 PDUFA date for second-line melanoma, drug demonstrates good results in front-line study. Will the data sway regulators?